Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Case studies in current drug development: 'glycylcyclines'.

Phaik-Eng Sum1

  • 1Chemical and Screening Sciences Department, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA. sump@wyeth.com

Current Opinion in Chemical Biology
|June 30, 2006
PubMed
Summary

Glycylcyclines, like Tygacil, are a new class of antibiotics effective against resistant bacteria. This drug shows broad-spectrum activity, including against MRSA, offering a vital option for treating challenging infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tigecycline: a case study.

Expert opinion on drug discovery·2013
Same author

Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.

Bioorganic & medicinal chemistry letters·2009
Same author

Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5.

Protein science : a publication of the Protein Society·2007
Same author

Simultaneous hydrogenolysis of p-nitrobenzyl esters and carbamates side-chains in the THF 1beta-carbapenem OCA-983 in biphasic media.

Medicinal chemistry (Shariqah (United Arab Emirates))·2006
Same author

Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.

Bioorganic & medicinal chemistry letters·2005
Same author

Synthesis and antibacterial activity of 9-substituted minocycline derivatives.

Bioorganic & medicinal chemistry letters·2005

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antibiotic resistance is a growing global health threat, necessitating the development of novel antimicrobial agents.
  • Tetracycline antibiotics are widely used but face resistance challenges from pathogens.
  • Glycylcyclines have emerged as a promising class of antibiotics to combat resistant bacteria.

Purpose of the Study:

  • To evaluate the antibacterial spectrum and efficacy of Tygacil, a novel glycylcycline antibiotic.
  • To assess Tygacil's activity against a broad range of clinically relevant pathogens, including resistant strains.

Main Methods:

  • In vitro and in vivo studies were conducted to determine Tygacil's antibacterial spectrum.
  • Evaluated activity against Gram-positive, Gram-negative, atypical, and anaerobic bacteria.

Related Experiment Videos

  • Assessed efficacy against bacterial strains with common tetracycline resistance mechanisms (efflux and ribosomal protection).

    • Main Results:

    • Tygacil demonstrated potent in vitro and in vivo activity against a wide array of bacterial pathogens.
    • The antibiotic was effective against Gram-positive, Gram-negative, atypical, and anaerobic bacteria.
    • Tygacil showed significant activity against strains exhibiting tetracycline resistance, including methicillin-resistant Staphylococcus aureus (MRSA).

    Conclusions:

    • Tygacil represents a significant advancement in antibiotic therapy, offering broad-spectrum coverage.
    • Its efficacy against multidrug-resistant Gram-positive pathogens, such as MRSA, makes it a valuable therapeutic option.
    • Tygacil addresses a critical need for effective treatments against challenging bacterial infections.